CERSI-PGx advances pharmacogenomics through five dedicated work packages (WPs), each focused on a core area of research, education, regulatory guidance, and patient involvement. Together, these WPs ensure a coordinated approach to integrating pharmacogenomics into UK healthcare and regulatory pathways.

• WP1 – Developing UK-Based Guidelines
• WP2 – Pathway for Industry Pharmacogenomic Testing
• WP3 – Education and Training
• WP4 – Health Economics of PGx
• WP5 – Patient and Public Engagement

WP1 – Developing UK-Based Guidelines

Leads: Professor Sir Munir Pirmohamed, Dr Cinzia Dello Russo
Purpose: Generate standard templates for UK pharmacogenomic guidelines and publish them for wide dissemination.

WP2 – Pathway for Industry Pharmacogenomic Testing

Leads: Mark Wigglesworth, Jackie O’Brien
Purpose: Define industry and regulatory issues, conduct gap analyses, streamline commercial assay accreditation, and design a regulatory portal.

WP3 – Education and Training

Leads: Dr Emma Magavern, Dr Maria Tsakiroglou
Purpose: Upskill stakeholders in pharmacogenomics and regulatory pathways through collaboration with the British Pharmacological Society and development of an educational platform.

WP4 – Health Economics of PGx

Leads: Professor Dyfrig Hughes, Dr Chris Sampson
Purpose: Assess the health, societal, and economic benefits of pharmacogenomics, conduct stakeholder consultations, and develop an economic model framework for NHS implementation.

WP5 – Patient and Public Engagement

Leads: Dr John McDermott, Dr Ramona Moldovan
Purpose: Integrate patient and public voices into regulatory decision-making, focusing on patient information leaflets and direct-to-consumer pharmacogenomic testing.